Outlook For Heart Failure Drugs Entresto And Corlanor Finally Looking Up
This article was originally published in The Pink Sheet Daily
New US and European cardiology guidelines recommend Novartis' Entresto and Amgen's Corlanor, and coverage for both is coming soon with one major insurer.
You may also be interested in...
Sales of Novartis' Entresto have been painfully slow and missed their 2016 target of $200m – but the big pharma hopes the heart failure drug's sales momentum will take off next year and it remains confident the first-in-class therapy will eventually reach peak annual sales of around $5bn.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.